Home/Filings/4/0000899243-21-014303

4//SEC Filing

Pillar Invest Corp 4

Accession 0000899243-21-014303

CIK 0000861838other

View on SEC.gov Company Profile

Filed

Mar 30, 8:00 PM ET

Accepted

Mar 31, 9:51 PM ET

Size

30.8 KB

Accession

0000899243-21-014303

Insider Transaction Report

Form 4

Period: 2021-01-20

IDERA PHARMACEUTICALS, INC.IDRA

Pillar Invest Corp

Director10% Owner

Transactions

Exercise of In-Money
Common Stock
2021-01-20$0.01/sh+643,525$6,435→ 1,931,893 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Sale
Common Stock
2021-03-18$1.80/sh+323,726$582,221→ 1,608,167 total(indirect: By Pillar Pharmaceuticals 6, L.P.)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+884,175$8,842→ 2,492,342 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−884,175$8,842→ 884,175 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (884,175 underlying)
Sale
Common Stock
2021-03-18$1.80/sh+1,376,039$2,474,806→ 4,121,599 total(indirect: By Foundation)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+1,611,634$16,116→ 5,733,233 total(indirect: By Foundation)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−1,611,634$16,116→ 1,611,634 total(indirect: By Foundation)
Exercise: $0.01From: 2020-12-11→ Common Stock (1,611,634 underlying)
Exercise of In-Money
Prefunded Warrants
2021-01-20$0.01/sh−643,525$6,435→ 643,525 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (643,525 underlying)

Holdings

Common Stock
(indirect: By Abude Umari See Footnotes)
386,110
Common Stock
(indirect: By Youssef El Zein See Footnotes)
26,308

Pillar Partners Foundation, L.P.

10% Owner

Transactions

Sale
Common Stock
2021-03-18$1.80/sh+323,726$582,221→ 1,608,167 total(indirect: By Pillar Pharmaceuticals 6, L.P.)
Exercise of In-Money
Prefunded Warrants
2021-01-20$0.01/sh−643,525$6,435→ 643,525 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (643,525 underlying)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−1,611,634$16,116→ 1,611,634 total(indirect: By Foundation)
Exercise: $0.01From: 2020-12-11→ Common Stock (1,611,634 underlying)
Exercise of In-Money
Common Stock
2021-01-20$0.01/sh+643,525$6,435→ 1,931,893 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Sale
Common Stock
2021-03-18$1.80/sh+1,376,039$2,474,806→ 4,121,599 total(indirect: By Foundation)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+1,611,634$16,116→ 5,733,233 total(indirect: By Foundation)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+884,175$8,842→ 2,492,342 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−884,175$8,842→ 884,175 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (884,175 underlying)

Holdings

Common Stock
(indirect: By Abude Umari See Footnotes)
386,110
Common Stock
(indirect: By Youssef El Zein See Footnotes)
26,308

Pillar Pharmaceuticals 6, L.P.

10% Owner

Transactions

Exercise of In-Money
Common Stock
2021-01-20$0.01/sh+643,525$6,435→ 1,931,893 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Sale
Common Stock
2021-03-18$1.80/sh+323,726$582,221→ 1,608,167 total(indirect: By Pillar Pharmaceuticals 6, L.P.)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+1,611,634$16,116→ 5,733,233 total(indirect: By Foundation)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−884,175$8,842→ 884,175 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (884,175 underlying)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+884,175$8,842→ 2,492,342 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Exercise of In-Money
Prefunded Warrants
2021-01-20$0.01/sh−643,525$6,435→ 643,525 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (643,525 underlying)
Sale
Common Stock
2021-03-18$1.80/sh+1,376,039$2,474,806→ 4,121,599 total(indirect: By Foundation)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−1,611,634$16,116→ 1,611,634 total(indirect: By Foundation)
Exercise: $0.01From: 2020-12-11→ Common Stock (1,611,634 underlying)

Holdings

Common Stock
(indirect: By Youssef El Zein See Footnotes)
26,308
Common Stock
(indirect: By Abude Umari See Footnotes)
386,110

Umari Abude

10% Owner

Transactions

Sale
Common Stock
2021-03-18$1.80/sh+323,726$582,221→ 1,608,167 total(indirect: By Pillar Pharmaceuticals 6, L.P.)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−1,611,634$16,116→ 1,611,634 total(indirect: By Foundation)
Exercise: $0.01From: 2020-12-11→ Common Stock (1,611,634 underlying)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−884,175$8,842→ 884,175 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (884,175 underlying)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+1,611,634$16,116→ 5,733,233 total(indirect: By Foundation)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+884,175$8,842→ 2,492,342 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Exercise of In-Money
Common Stock
2021-01-20$0.01/sh+643,525$6,435→ 1,931,893 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Sale
Common Stock
2021-03-18$1.80/sh+1,376,039$2,474,806→ 4,121,599 total(indirect: By Foundation)
Exercise of In-Money
Prefunded Warrants
2021-01-20$0.01/sh−643,525$6,435→ 643,525 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (643,525 underlying)

Holdings

Common Stock
(indirect: By Abude Umari See Footnotes)
386,110
Common Stock
(indirect: By Youssef El Zein See Footnotes)
26,308

ZEIN YOUSSEF EL

Director

Transactions

Sale
Common Stock
2021-03-18$1.80/sh+1,376,039$2,474,806→ 4,121,599 total(indirect: By Foundation)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+1,611,634$16,116→ 5,733,233 total(indirect: By Foundation)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−884,175$8,842→ 884,175 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (884,175 underlying)
Sale
Common Stock
2021-03-18$1.80/sh+323,726$582,221→ 1,608,167 total(indirect: By Pillar Pharmaceuticals 6, L.P.)
Exercise of In-Money
Common Stock
2021-03-26$0.01/sh+884,175$8,842→ 2,492,342 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)
Exercise of In-Money
Prefunded Warrants
2021-01-20$0.01/sh−643,525$6,435→ 643,525 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnote)
Exercise: $0.01From: 2020-12-11→ Common Stock (643,525 underlying)
Exercise of In-Money
Prefunded Warrants
2021-03-26$0.01/sh−1,611,634$16,116→ 1,611,634 total(indirect: By Foundation)
Exercise: $0.01From: 2020-12-11→ Common Stock (1,611,634 underlying)
Exercise of In-Money
Common Stock
2021-01-20$0.01/sh+643,525$6,435→ 1,931,893 total(indirect: By Pillar Pharmaceuticals 6, L.P. See Footnotes)

Holdings

Common Stock
(indirect: By Abude Umari See Footnotes)
386,110
Common Stock
(indirect: By Youssef El Zein See Footnotes)
26,308

Footnotes (7)

[F1]The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $1.72-$1.85. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The shares were sold to close two margin loans and the Pillar Funds do not currently have any other margin loans.
[F2]Pillar Invest Corporation ("Pillar GP") is the general partner of Pillar Pharmaceuticals I, L.P., Pillar Pharmaceuticals II, L.P., Pillar Pharmaceuticals III, L.P., Pillar Pharmaceuticals IV, L.P., Pillar Pharmaceuticals V, L.P., Pillar Pharmaceuticals 6, L.P. ("Pillar 6") and Pillar Partners Foundation, L.P. (collectively, the "Pillar Funds"). Youssef El Zein and Abude Umari are directors of Pillar GP. Each of Pillar GP, Mr. El Zein and Mr. Umari disclaims Section 16 beneficial ownership of the securities beneficially owned by the Pillar Funds and this report shall not be deemed an admission that any of Pillar GP, Mr. El Zein or Mr. Umari is the Section 16 beneficial owner of any such securities, except to the extent of its or his pecuniary interest therein, if any, by virtue of its or his ownership interest in the Pillar Funds or Pillar GP, as applicable.
[F3]1,611,634 of such warrants beneficially owned and exercised for shares of common stock by Pillar Partners, of which Pillar GP is the general partner (the "Pillar Partners Warrants") and 884,175 of such warrants exercised by Pillar 6 (the "Pillar 6 Warrants"). Pillar GP disclaims Section 16 beneficial ownership of the Pillar Partners Warrants and the Pillar 6 Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar Partners Warrants or Pillar 6 Warrants.
[F4]643,525 of such warrants exercised by Pillar 6 (the "Pillar 6 January Warrants"). Pillar GP disclaims Section 16 beneficial ownership of the Pillar 6 January Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar 6 January Warrants.
[F5]On March 4, 2021, Pillar 6 distributed in-kind, without consideration, 187,600 shares of Common Stock to Abude Umari, in accordance with his pro rata interest in Pillar 6. This distribution was made in accordance with the exemptions under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended.
[F6]Includes the shares received by Mr. Umari in the distribution reported in footnote (5).
[F7]The Pre-funded warrants have no expiration date.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

IDERA PHARMACEUTICALS, INC.

CIK 0000861838

→

Entity typeother

IncorporatedCayman Islands

Related Parties

filerCIK 0001534428

Filing Metadata

Form type: 4
Filed: Mar 30, 8:00 PM ET
Accepted: Mar 31, 9:51 PM ET
Size: 30.8 KB

View on SEC.gov